These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study. Nugent AC; Wills KE; Gilbert JR; Zarate CA Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012 [TBL] [Abstract][Full Text] [Related]
5. Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. Rivas-Grajales AM; Salas R; Robinson ME; Qi K; Murrough JW; Mathew SJ Int J Neuropsychopharmacol; 2021 May; 24(5):383-391. PubMed ID: 33249434 [TBL] [Abstract][Full Text] [Related]
6. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436 [TBL] [Abstract][Full Text] [Related]
7. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans. Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335 [TBL] [Abstract][Full Text] [Related]
8. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782 [TBL] [Abstract][Full Text] [Related]
10. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Su TP; Chen MH; Li CT; Lin WC; Hong CJ; Gueorguieva R; Tu PC; Bai YM; Cheng CM; Krystal JH Neuropsychopharmacology; 2017 Dec; 42(13):2482-2492. PubMed ID: 28492279 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study. Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333 [TBL] [Abstract][Full Text] [Related]
12. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Salvadore G; Cornwell BR; Sambataro F; Latov D; Colon-Rosario V; Carver F; Holroyd T; DiazGranados N; Machado-Vieira R; Grillon C; Drevets WC; Zarate CA Neuropsychopharmacology; 2010 Jun; 35(7):1415-22. PubMed ID: 20393460 [TBL] [Abstract][Full Text] [Related]
13. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406 [TBL] [Abstract][Full Text] [Related]
15. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118 [TBL] [Abstract][Full Text] [Related]
16. Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial. Zolghadriha A; Anjomshoaa A; Jamshidi MR; Taherkhani F BMC Psychiatry; 2024 May; 24(1):341. PubMed ID: 38714931 [TBL] [Abstract][Full Text] [Related]
17. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study. Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769 [TBL] [Abstract][Full Text] [Related]
18. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061 [TBL] [Abstract][Full Text] [Related]
19. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273 [TBL] [Abstract][Full Text] [Related]
20. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]